CaTe

What CaTe does

CaTe Inc. (株式会社CaTe) is a Japanese medical device company founded in March 2020 by Dr. Kazuhiro Terashima (寺嶋 一裕), a practicing cardiologist, to address limited access to cardiac rehabilitation services in Japan. The company develops a single core product — a Class II cardiac rehabilitation program medical device application that uses IoT and AI technologies to deliver remote, home-based rehabilitation programs for patients with heart disease, enabling treatment continuity outside traditional clinical settings. CaTe holds a Class II Medical Device Manufacturing and Sales License (13B2X10514) issued by the Tokyo Metropolitan Government in March 2022, and operates from offices in Tokyo (Bunkyo ward, headquarters) and Nagoya (within the STATION Ai facility).

The company sells its product through direct medical institution channels in Japan and has not publicly disclosed pricing or revenue. As of January 2026, CaTe has raised cumulative funding of approximately 3.5 billion yen (~$23.6M USD) across multiple instruments, including a 100M yen pre-seed from Coral Capital (December 2021), a 40M yen seed from Samurai Incubate (May 2022), a 400M yen Series A co-led by Jafco Group and Tokyo Wellness Impact Fund (July 2023), additional non-dilutive support of up to 190M yen via the NEDO DTSU program (January 2024), a 1.58–1.73 billion yen Series B in August–December 2025, and selection for the NEDO DTSU PCA phase (January 2026) intended to support clinical trials and global expansion of the cardiac rehabilitation medical device business.

Name

CaTe

Legal name

株式会社CaTe（CaTe Inc.）

Website

https://cate.co.jp

Company type

Private

Founded year

2020

Operating status

Operating

Short description

CaTe is a Japanese medical device company that uses IoT and AI to develop and sell a remote cardiac rehabilitation system, serving heart disease patients who need treatment outside hospital settings through direct sales to medical institutions in Japan.

Ownership category

akta.pro rank

Product category

Cardiac Rehabilitation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (5132)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Cardiac Rehabilitation & Secondary Prevention (HLAKABAJ)

akta.pro secondary industries

Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT) (HLACAPAE), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Cardiology Telemedicine Platforms (HLALAGAB)

Keywords

• Remote cardiac rehabilitation
• Cardiac rehab medical devices
• IoT healthcare technology
• AI cardiac monitoring
• Telerehabilitation software

Headquarters

HQ city

Hongo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

CaTe develops and sells a regulated Class II medical device software application that delivers remote cardiac rehabilitation programs to patients with heart disease. The product combines IoT data capture with AI-driven personalization to enable patients to conduct cardiac rehabilitation at home rather than only in clinical settings, expanding access to continuous cardiac care.

Product overview

CaTe offers a single core product: a cardiac rehabilitation program medical device application that enables remote cardiac rehabilitation for heart disease patients. The company combines IoT and AI technologies to deliver personalized rehabilitation programs, allowing patients to conduct cardiac rehabilitation at home rather than only in clinical settings.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiac Rehabilitation Program Medical Device (心臓リハビリプログラム医療機器) A regulated Class II medical device application that delivers remote cardiac rehabilitation programs to heart disease patients, enabling home-based treatment that previously required hospital visits. Combines IoT data capture with AI-driven personalization to support continuous cardiac care. Sold to hospitals and medical institutions in Japan for prescription to cardiac patients.

Quantifiable outcome

• Remote cardiac rehabilitation systems for patients with heart disease

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Recora Health: US-based virtual cardiac rehabilitation platform providing home-based cardiac rehab programs with monitoring and coaching. Most direct global comparable to CaTe's remote cardiac rehab offering, operating in a different geography but with a near-identical product thesis.
• Movn Health: US-based virtual cardiac rehabilitation company delivering remote cardiac rehab programs to health systems and payers. Directly competes with CaTe in concept and care delivery model, focused on post-event cardiac recovery.
• Heartbeat Health: US cardiology-focused virtual care platform offering telemedicine, remote monitoring, and longitudinal heart care. Comparable to CaTe as a specialty cardiology telehealth provider with continuous remote patient management.
• CureApp: Japanese digital therapeutics company developing PMDA-approved therapeutic apps for hypertension and other conditions. Closest Japanese peer with a similar model of regulated medical device software delivering clinical interventions.

Emerging players

• Biofourmis: AI-powered remote patient monitoring and virtual care platform with cardiovascular focus. Comparable technology stack (IoT + AI for continuous monitoring) and overlap with CaTe's home-based cardiac monitoring use cases.
• Eko Health: Maker of AI-powered digital stethoscopes and cardiac monitoring devices with FDA-cleared telehealth platform for cardiac assessment. Comparable as a connected medical device company entering cardiac remote care.
• VitalConnect: Provider of wearable biosensor patches and remote cardiac monitoring platform for hospital and home use. Comparable as a connected medical device + software platform focused on continuous cardiac monitoring.

Broad incumbents

• Omron Healthcare: Major Japanese medical device company producing blood pressure monitors, ECG devices, and connected cardiovascular health products. Broad incumbent in the same Japanese cardiovascular monitoring market where CaTe operates.
• Fukuda Denshi: Established Japanese manufacturer of cardiology diagnostic equipment including ECG, patient monitors, and cardiovascular measurement devices. Broad incumbent in Japanese cardiology device space with overlapping customer base of hospitals and clinics.
• Philips (Cardiac Care): Global medtech giant with cardiac rehabilitation, remote patient monitoring, and connected care portfolio including wearable biosensors. Broad incumbent competing with CaTe in hospital-based cardiac care and remote monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CaTe